Denali announced a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases that could be worth more than $1 billion.
Dicerna Pharmaceuticals and Eli Lilly struck a deal to use an RNAi technology platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.
Novo Nordisk is in advanced talks to acquire assets to bolster the company’s struggling biopharma business after the drugmaker announced the hiring of an AstraZeneca executive to head the unit.
Watertown, Mass.-based SQZ Biotechnologies could be on the receiving end of up to $1 billion following the company’s signing of an expansion agreement with pharma giant Roche.
Emeryville, Calif.-based Berkeley Lights closed on a $95 million financing round, led by Nikon.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.
Boston Pharmaceuticals licenses a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.
Janssen Biotech informed Aduro Biotech that the Johnson & Johnson company was terminating a research and license deal related to Aduro’s Listeria treatment for cancers.